20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

D.Henry; R.von Moos; S.Vadhan-Raj; V.Hungria; A.Spencer; V.Hirsh; J.Wang; S.Jun; H.Yeh; R.Dansey

首页> 外文期刊>European Journal of Cancer Supplements >20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

【24h】

20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

机译：20LBA地诺单抗和唑来膦酸用于治疗晚期癌症（乳腺癌和前列腺癌除外）或多发性骨髓瘤患者的骨转移的双盲，随机研究

获取原文

开具论文收录证明 >>

AI期刊论文写作 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第3期|共1页
作者
D.Henry; R.von Moos; S.Vadhan-Raj; V.Hungria; A.Spencer; V.Hirsh; J.Wang; S.Jun; H.Yeh; R.Dansey;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma [J] . D.Henry, R.von Moos, S.Vadhan-Raj, European Journal of Cancer Supplements . 2009,第3期

机译：20LBA地诺单抗和唑来膦酸用于治疗晚期癌症（乳腺癌和前列腺癌除外）或多发性骨髓瘤患者的骨转移的双盲，随机研究
2. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. [J] . Henry DH, Costa L, Goldwasser F, Journal of Clinical Oncology . 2011,第9期

机译：地诺单抗和唑来膦酸在晚期癌症（乳腺癌和前列腺癌除外）或多发性骨髓瘤患者的骨转移治疗中的随机，双盲研究。
3. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. [J] . Stopeck AT, Lipton A, Body JJ, Journal of Clinical Oncology . 2010,第35期

机译：地诺单抗与唑来膦酸治疗晚期乳腺癌骨转移的比较：一项随机，双盲研究。
4. Radium-223 Dichloride Monotherapy and Combination Therapy with Zoledronic Acid or Doxorubicin Improve Survival in a Mouse Model of Breast Cancer Bone Metastasis [C] . Jukka Rissanen, Mari Suominen, Rami K?k?nen, Molecular Medicine TRI-CON. . 2014

机译：镭-223二氯化物单疗法和组合治疗唑醇或多柔比星改善了乳腺癌骨转移的小鼠模型中的存活
5. Treatment discontinuation among breast, colorectal, and prostate cancer patients in Alabama [D] . Melhado, Trisha V. 2009

机译：在阿拉巴马州的乳腺癌，结肠直肠癌和前列腺癌患者中终止治疗
6. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised double-blind study [O] . Karim Fizazi, Michael Carducci, Matthew Smith, -1

机译：狄诺塞麦对唑来膦酸用于治疗骨转移的男性去势抗性前列腺癌：随机双盲研究
7. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study [O] . Karim Fizazi, Michael Carducci, Matthew Smith, 2011

机译：Denosumab与唑醇酸酸抗阉割前列腺癌中骨转移的影响：随机，双盲研究

20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

著录项

引文网络

相似文献

相关主题

期刊订阅